Vaxcyte, Inc. logo

Vaxcyte, Inc.

NASDAQ:PCVX

Overview | Financials
Company Name Vaxcyte, Inc.
Symbol PCVX
Currency USD
Price 31.45
Market Cap 4,057,018,550
Dividend Yield 0%
52-week-range 27.66 - 121.055
Industry Biotechnology
Sector Healthcare
CEO Mr. Grant E. Pickering M.B.A.
Website https://vaxcyte.com

An error occurred while fetching data.

About Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to

Related Stocks

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

SUPN

31.54 USD

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

9.69 USD

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

35.54 USD

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

20.44 USD

Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

137.17 USD

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

2.09 USD

Financials

Numbers are in millions USD

Numbers are in millions USD